Secondary Publication: COVID-19 Pandemic: Drug Development and Treatment

Fujiko Tsukahara; Yoshiro Maru

doi:10.24488/twmuj.2021004

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019. It has been rapidly spreading worldwide ever since. The majority of COVID-19 infections are asymptomatic or mildly symptomatic. However, old age or comorbidities can result in a cytokine storm, which eventually leads to death. To date, no drug has been clinically proven effective to treat COVID-19, and development of effective drugs against SARS-CoV-2 is urgently required. Several drugs used in treating other diseases are being evaluated. Clinical trials on many new antiviral drugs and vaccine candidates are also rapidly ongoing. In this review, we summarized the currently used drugs and newly developed vaccines for the treatment of COVID-19.

This is a secondary publication of "COVID-19 Pandemic: Drug Development and Drug Treatment" published in the Journal of Tokyo Women's Medical University (in Japanese) 91 (1): 19-28, 2021.

Content from these authors

This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.
https://creativecommons.org/licenses/by/4.0/deed.ja

Favorites & Alerts

Corresponding author

Register with J-STAGE for free!